Related Experiment Video
Updated: Apr 16, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
20.2K
Cabergoline use for pituitary tumors and valvular disorders
Renata S Auriemma1, Rosario Pivonello2, Lucia Ferreri2
1Ios-Coleman Medicina Futura Medical Center, Centro Direzionale, Naples 80143, Italy.
Endocrinology and Metabolism Clinics of North America
|March 4, 2015
Summary
Cabergoline treatment for pituitary tumors generally does not increase cardiac valve disease risk. Studies show no link between cabergoline use and valvulopathy, regardless of duration or dose.
Area of Science:
- Endocrinology
- Cardiology
- Oncology
Background:
- Cabergoline (CAB) is a primary medical treatment for pituitary tumors, especially those causing hormone overproduction.
- A potential link between cabergoline use and cardiac valve disease in patients with pituitary tumors remains a subject of ongoing discussion.
Purpose of the Study:
- To review existing literature on the cardiac safety of cabergoline in pituitary tumor patients.
- To assess the association between cabergoline treatment and the incidence of clinically significant cardiac valve disease.
Main Methods:
- Systematic review of studies investigating cabergoline's effects on cardiac valves.
- Analysis of reported cases of valvulopathy in patients treated with cabergoline for pituitary tumors.
Main Results:
- The majority of studies indicate that cabergoline is not associated with an increased risk of significant valvulopathy.
- No correlation was found between the duration or cumulative dose of cabergoline and the development of valvular abnormalities.
Conclusions:
- Current evidence suggests cabergoline is safe concerning cardiac valve health in pituitary tumor patients.
- Further research may be warranted, but existing data do not support a causal link between cabergoline and cardiac valve disease.
Keywords:
AcromegalyCabergolineCardiac valve diseaseCushing’s diseaseDopamine-agonistsPituitary adenomaProlactinomaMore Related Videos
Related Concept Videos
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.1K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:26Cholinergic Antagonists: Therapeutic Uses
1.8K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.8K